Home  |  Contact

Cellosaurus LR-SKBR3 (CVCL_A2GI)

[Text version]

Cell line name LR-SKBR3
Accession CVCL_A2GI
Resource Identification Initiative To cite this cell line use: LR-SKBR3 (RRID:CVCL_A2GI)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
Sequence variations Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0033 (SK-BR-3)
Sex of cell Female
Age at sampling 43Y
Category Cancer cell line
Publications

PubMed=32942617; DOI=10.3390/cancers12092630
Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.
HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib attenuates acquired lapatinib-resistance in ER-positive, HER2-overexpressing breast cancer cell line.
Cancers (Basel) 12:2630.1-2630.16(2020)

Cross-references
Other Wikidata; Q105509950
Entry history
Entry creation12-Jan-2021
Last entry update20-May-2021
Version number2